Pharma and biotech organizations often assume content strategy should look the same across the industry. Regulatory submissions follow shared guidelines and present similar information in similar places, largely due to the decades-old Common Technical Document (CTD) that is built into submission management software and wedged into every medical writer’s brain.
In practice, however, regulatory reviewers see significant variation in what content is included, how it is structured, and where it appears, even within submissions from the same company. This variation is more than cosmetic. It slows regulatory review, impedes comprehension, and can introduce delays when regulators must request clarification. These issues rarely stem from writing quality alone. They reflect content strategies that are not designed for how organizations actually operate.
→ Read more: Writing for structured content in pharma – what you need to know
Why content strategy is not one-size-fits-all in pharma
A content strategy is a business strategy. In regulated environments, the content strategy must reflect organizational realities, operational constraints, and transformation priorities. Three factors make a universal structured content strategy unrealistic.
Organizational operating models vary
Regulatory content in pharma and biotech is created across multiple functions, including R&D, clinical operations, regulatory affairs, pharmacovigilance, and CMC. These teams often operate under different models:
- Centralized vs. federated governance
- Internal authors vs. outsourced partners
- Agile workflows vs. highly controlled processes
When the structured content strategy ignores these differences, people will struggle with adoption, regardless of how advanced their shiny new technology is. Effective content strategies account for distributed authorship, clear ownership, and realistic review models.
Balancing rigor and flexibility
Highly prescriptive structured content strategies enable consistency, reuse, and automation. This level of rigor can significantly reduce review cycles and rework. Medical and regulatory writers focus on creating de novo content specific to the current need while leveraging existing content for information that does not need to change.
At the same time, many organizations need flexibility to support novel study designs, evolving portfolios, or accelerated timelines. Overly rigid structures often lead to workarounds that undermine both quality and efficiency.
The most effective content strategies balance the need for rigor and flexibility. This balance not only serves different organizational cultures, it also provides a spectrum for content governance. Some content can be held to strict standardization rules, where the structure, metadata, and terminology must not change. Other content can be granted more leeway in structure and the level of standardization.
Transformation priorities shape the strategy
Structured content supports many goals, but not all organizations are optimizing for the same outcome at the same time. Common priorities include:
- Faster content development cycles enabled by automation
- Accuracy and completeness of updates and amendments
- Content reuse to eliminate unnecessary re-verification of data and content
- AI-enabled analytics and insight generation
- Full traceability and audit trails
- Reduced translation and localization costs
The right content strategy aligns with the business outcomes that will deliver measurable value first, rather than attempting to solve every problem simultaneously.
Structured content as the foundation for AI in pharma
The push to adopt AI across regulatory and clinical operations has accelerated interest in structured content. AI systems depend on well-structured content enriched with meaningful metadata to produce reliable, traceable results.
Without structure and governance:
- AI outputs are difficult to validate
- Reuse becomes unreliable
- Risk increases instead of decreases
Regulators have begun to release guidelines for sponsors to align with when incorporating AI into content generation. Most structured content systems today support AI integrations to enable the enterprise to make their internal AI solutions available to authors. Medical and regulatory writing teams are using AI to enable content planning, verify content standardization and quality, and to draft and revise text.
Structured content provides value beyond automatic formatting of documents and other outputs. Structure is the bridge between “content” and “data.” Structure makes content findable and usable by machines (including AI solutions) as well as by humans.
With structured content, organizations can capture knowledge once and reuse it across submissions, clinical trial registries, study start-up materials, electronic data capture systems, and intelligent design tools.
A structured content strategy helps ensure alignment across the organization. No matter where content is created, it must be structured and tagged in a standardized way. This consistency improves the ability of AI and other machines to find, exchange, and use information.
→ Read more: Pharma content reuse
Let your content be your guide
One of best kept secrets of content strategy design is that most organizations have already made several strategic decisions about component granularity (guidelines for when to separate content into individual chunks) and content reuse (guidelines and rules for when to reuse content). These decisions about components and reuse are typically buried in pages of authoring instructions provided in the Word documents that medical writers use as templates.
For example, authoring instructions often describe if/then conditions. An if/then condition is a rule that drives the inclusion of content. If the condition is met, the content must be included.
An if/then instruction typically says something like “for vaccine studies only, include this sentence” or “for medical device studies only, include this paragraph.” This same instruction might appear in six or more places in a single Word document.
These repeating patterns are the first indication of content reuse opportunities. Each unit of content that meets the condition can be chunked into a single component. The component is tagged with metadata that identifies its applicability, such as “vaccine” or “medical device.”
By applying this metadata consistently throughout your component library, you enable machine processing and human efficiency. Here are just some examples:
- Improve findability. A search for “vaccine” will return components that are relevant to vaccines even if the word “vaccine” does not appear in the text.
- Filter search results. Search results for “medical device” can be further refined by filters such as device name or model.
- Provide context for AI. Metadata helps AI systems distinguish between similar text that applies to very different subjects. A safety description that is worded similarly for vaccine studies and oncology studies might have very different contexts. Metadata helps mitigate the risk that AI summaries provide the wrong context.
- Enable automated content assembly. Metadata enables systems to retrieve content, assemble it into an outline, and reuse existing content automatically.
- Enable image search. A search for the device name will return images that illustrate the device. Metadata is the primary enabler of image search since there is no text.
When an organization fails an attempt to adopt structured content, it is often because they did not analyze the content from a database or knowledge management perspective. It is common (and understandable) for teams to simply break up their Word documents at every heading and put that content into the new structured content management system.
This “lift and shift” approach can be a way to get people working in the new system faster. However, if you stop there and do not truly restructure and optimize your content for reuse, you will not reap the full benefits and you will waste some of your investment in the new technology.
From documents to managed knowledge
A structured content strategy defines:
- What knowledge is captured, and at what level of granularity
- How that knowledge is reviewed, governed, and versioned
- How it is reused and assembled into fit-for-purpose outputs
This shift allows organizations to move beyond repeatedly authoring documents toward managing a living, reusable knowledge base that supports compliance, efficiency, and innovation.
→ Read more: Why structured content is critical for AI readiness
The bottom line
Technology supports structured content strategy, but it cannot replace it. Sustainable transformation requires alignment across people, process, and structure.
In pharma and biotech, a tailored structured content strategy reduces regulatory friction, improves reuse, and lays the groundwork for AI-driven workflows. The goal is not uniformity for its own sake, but clarity, consistency, and scalability where they matter most.
